Within NSCLC, the effective and comprehensive characterization of individual drivers and resistance mutations in key biomarkers, including EGFR and ALK, holds the key to the personalization of NSCLC treatment selection and monitoring [2]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.